Found a very interesting article on a trial done in Switzerland regarding quality of life in MCRPC patients who took different second-line treatments after ADT and Docetaxel chemotherapy. So many of the guidelines for second-line treatments I've found refer to "Chemotherapy-Naive" patients.
Here, they are comparing those who used Cabazitaxel chemotherapy as second-line to "other treatments" which were mostly Zytiga from what I could see. At the time of study, Enzalutamide was not yet licensed in Switzerland so not included. It's a very interesting article so thought I would share it.